These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 8923805)
1. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans. Shen J; Davis LE; Wallace JM; Cai Y; Lawson LD Planta Med; 1996 Oct; 62(5):415-8. PubMed ID: 8923805 [TBL] [Abstract][Full Text] [Related]
2. In vitro synergism of concentrated Allium sativum extract and amphotericin B against Cryptococcus neoformans. Davis LE; Shen J; Royer RE Planta Med; 1994 Dec; 60(6):546-9. PubMed ID: 7809209 [TBL] [Abstract][Full Text] [Related]
3. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole. Khyriem AB; Sujatha S; Parija SC Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750 [TBL] [Abstract][Full Text] [Related]
4. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. Wang H; Xu K; Liu L; Tan JP; Chen Y; Li Y; Fan W; Wei Z; Sheng J; Yang YY; Li L Biomaterials; 2010 Apr; 31(10):2874-81. PubMed ID: 20044131 [TBL] [Abstract][Full Text] [Related]
5. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122 [TBL] [Abstract][Full Text] [Related]
6. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology. Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042 [TBL] [Abstract][Full Text] [Related]
7. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp. Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870 [TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome. Poon M; Cronin DC; Wormser GP; Bottone EJ Arch Pathol Lab Med; 1988 Feb; 112(2):161-2. PubMed ID: 3276290 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. Barchiesi F; Giacometti A; Cirioni O; Arzeni D; Silvestri C; Kamysz W; Abbruzzetti A; Riva A; Kamysz E; Scalise G Peptides; 2007 Aug; 28(8):1509-13. PubMed ID: 17698253 [TBL] [Abstract][Full Text] [Related]
10. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027 [TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis. Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679 [TBL] [Abstract][Full Text] [Related]
12. In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole. Wei GX; Bobek LA J Antimicrob Chemother; 2004 May; 53(5):750-8. PubMed ID: 15073161 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Schwarz P; Dromer F; Lortholary O; Dannaoui E Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675 [TBL] [Abstract][Full Text] [Related]
14. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Bii CC; Makimura K; Abe S; Taguchi H; Mugasia OM; Revathi G; Wamae NC; Kamiya S Mycoses; 2007 Jan; 50(1):25-30. PubMed ID: 17302744 [TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs. Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448 [TBL] [Abstract][Full Text] [Related]
16. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole. Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the in vitro activity of amphotericin B by time-kill curve methodology against large and small capsulate C. neoformans isolates. Córdoba S; Afeltra J; Vitale RG Diagn Microbiol Infect Dis; 2011 Nov; 71(3):260-2. PubMed ID: 21917396 [TBL] [Abstract][Full Text] [Related]
18. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans. Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410 [TBL] [Abstract][Full Text] [Related]
19. Synergistic antiyeast activity of garlic oil and allyl alcohol derived from alliin in garlic. Chung I; Kwon SH; Shim ST; Kyung KH J Food Sci; 2007 Nov; 72(9):M437-40. PubMed ID: 18034739 [TBL] [Abstract][Full Text] [Related]
20. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil. Almeida AM; Matsumoto MT; Baeza LC; de Oliveira E Silva RB; Kleiner AA; Melhem Mde S; Mendes Giannini MJ; FEMS Yeast Res; 2007 Jan; 7(1):152-64. PubMed ID: 17311593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]